The European Medicines Agency (EMA) has published earlier this month a report emphasizing the importance of SMEs in pharmaceutical innovation and draws attention to the trends observed in the past ten years. “The report shows that EMA’s tools to support pharmaceutical innovation by SMEs, and in particular scientific advice, are being increasingly used,” explains Melanie Carr, Head of EMA’s Stakeholders and Communication Division. “Encouraging small enterprises to engage in dialogue with us early in the product development is a priority for EMA as the input we provide allows them to optimise their development programme and generate high quality data on a medicine’s benefits and risks.”
Source: http://www.ema.europa.eu/